Alligator Bioscience AB

Alligator Bioscience Q2 2024 Earnings Call Alligator Bioscience will host a livestream (in English) for investors, analysts and media on Thursday, July 11, 2024, at 4:15 PM CEST/10:15 AM EDT. Alligator will publish its Q2 report on Thursday, July 11, 2024, at 8:00 AM CEST.

Psst! Out today - Alligator Bioscience AB's half-year report for 2024! Check out the corresponding PR: https://lnkd.in/dJg_85BH and don't miss our conference call today, at 4:15 pm CEST, over on our Youtube channel, where CEO Søren Bregenholt, CFO Marie Svensson and CMO Dr Sumeet Ambarkhane, MD will present and comment on the report. 👉 https://lnkd.in/dhEpyD2G

Pssst! 🐊 Don't miss today's BioStock - Connecting Innovation and Capital piece on Alligator Bioscience AB, with CEO Søren Bregenholt commenting on the latest #OPTIMIZE1 data. Follow the post link... 👉

🌟 SUBSTANTIAL OVERALL SURVIVAL BENEFIT AND UNPRECEDENTED DURATION OF RESPONSE! 🌟 Today we’re both proud and excited to announce the results from the 18-month follow-up analysis of #OPTIMIZE1, Alligator’s Phase 2 trial with #mitazalimab in first-line #pancreaticcancer. For an answer to the natural question, “Why?”, let us just start with: ·     Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously reported for FOLFIRINOX ·     Further deepening of tumor shrinkage was evident with additional objective responses over long treatment duration ·     Results demonstrate an unprecedented median Duration of Response of 12.6 months and confirm immunotherapeutic contribution of mitazalimab when added to chemotherapy ·     With a median 18-month follow-up duration, these results from the ongoing OPTIMIZE-1 trial validate and strengthen mitazalimab’s previously reported robust clinical benefit As CEO Søren Bregenholt puts it: “These latest results from the OPTIMIZE-1 study of our lead asset provide a strong validation of the clear and sustained clinical benefit produced by mitazalimab when combined with mFOLFIRINOX in the treatment of first-line pancreatic cancer. In fact, mitazalimab increases your chance of being alive at the 18-month mark by 95 percent, compared to published FOLFIRINOX data. These highly promising outcomes warrant continued clinical development of mitazalimab in a confirmatory setting and we are committed to bringing mitazalimab to pancreatic cancer patients as fast as possible.” For the full PR, just follow this link. 👉 https://lnkd.in/dVgcV5Fr

Excited to share that positive Phase 2 results from our #OPTIMIZE1 trial with #mitazalimab will be presented at #ESMOGI24! 🎉 This marks another milestone, building on the recent Alligator Bioscience AB's presentations at ASCO and the publication in The Lancet Oncology. Details of the upcoming presentation: 📄 CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma: A primary analysis of the OPTIMIZE-1 phase 1b/2 study 🎤 Type: Oral Presentation ⏰ Time: Saturday, June 29, 8:45 AM CET 📍 Location: Room 13a 👤 Presenter: Prof. Teresa Macarulla Mercade, MD, PhD, Vall d’Hebron, Barcelona Mitazalimab’s potential to improve treatment outcomes is a beacon of hope for patients and families affected by mPDAC. Join us to learn more about this groundbreaking research. Follow the post link to read today’s press release! 🐊

📢 Thrilled to announce that Johan Gileus will join Alligator Bioscience AB as CFO starting August 12, 2024. With over 25 years of financial leadership, Johan brings a wealth of experience from overseeing significant projects such as Phase 3 clinical trials and outlicensing in Japan. Join us in welcoming Johan to the Alligator family. His expertise will undoubtedly be invaluable as we forge ahead in our mission to develop groundbreaking treatments for hard-to-treat cancers. 🐊 Want to read more? Follow the post link. 👉

Don't miss Alligator Bioscience AB's CEO Søren Bregenholt at Aktiespararna's event Aktiedagarna i Stockholm today. 🐊 📍https://lnkd.in/dc3XC9e9 ⏰ 7.35 pm CEST // 1.35 pm EDT Check out the link above to register and attend the event - the presentation will be held in English.

Can't get enough of Alligator Bioscience AB and our latest newsflow? 🐊 Of course you can't! .. and of course we've got you covered. Check out today's BioStock - Connecting Innovation and Capital interview with CEO Søren Bregenholt commenting on the significance of our latest publication. Just follow the post link.  👉

🌟 Exciting News from Alligator Bioscience! 🌟 We are thrilled to announce that our Phase 2 #mitazalimab #pancreaticcancer data has been published in The Lancet Oncology, one of the world’s leading clinical oncology journals. This publication validates the quality and potential implications of our Phase 2 OPTIMIZE-1 results; results which were also presented on June 1, at the #ASCO2024 annual meeting. Comments CEO Søren Bregenholt: "“This publication in The Lancet Oncology is an important validation of the highly promising results of our OPTIMIZE-1 mitazalimab study. A substantial number of patients were either in the treatment or in the follow-up at the time of the primary analysis. Consequently, the 18-month survival follow-up data, which we expect at the end of June 2024, should provide further important insights into the potential of mitazalimab" Stay tuned for updated data with longer follow-up expected at the end of June 2024. In the meantime - check out today's press release following the post link. 👉 

Out today - another scientific publication by our brilliant Alligators! 🐊 Today's PR with the highlights found here 👉 https://lnkd.in/dbA6Mm9u .. aaand for the full article 👉 https://lnkd.in/drWJ6xbr Great work Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, Karin Enell Smith, Karin Hägerbrand, Malin Lindstedt and Peter Ellmark! 🌟